(Q46333356)

English

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

scientific article published in November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

positron emission tomography

1 reference

based on heuristic

inferred from title

Pier Luigi Zinzani

10

object named as

Pier Luigi Zinzani

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Gerardo Musuraca

object named as

Gerardo Musuraca

2

0 references

Enrico Derenzini

object named as

Enrico Derenzini

1

0 references

Michele Baccarani

9

object named as

Michele Baccarani

1 reference

Europe PubMed Central

21 December 2017

author name string

Stefano Fanti

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Vittorio Stefoni

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Monica Tani

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Lapo Alinari

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Filippo Venturini

7

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Letizia Gandolfi

8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

113

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

9

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

2496-2503

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

Treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of positron emission tomography (PET) in the management of lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23861

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23861

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18833583

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46333356&oldid=2105752706"